RFK Jr. eases access to unproven peptides despite opposition from FDA scientists
HHS published an interim enforcement policy for compounding six peptide substances while rulemaking continues.
TL;DR
- The rule covers six named substances: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.
- The Federal Register says the policy concerns enforcement discretion during rulemaking; it is not FDA approval.
- FDA scientific staff opposed the change, according to AP’s reporting.
HHS published an interim policy on October 30 describing circumstances in which it does not intend to take enforcement action against certain licensed compounders using six named peptide substances. The policy applies while the 503A bulk-substance list is developed through rulemaking. [1] [2]
The substances named are BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The Federal Register notice frames the action as enforcement discretion and does not add them to an approved-drug list. [1]
The Associated Press reported that FDA scientific staff had limited input in developing the policy and opposed the change. AP said HHS used a non-enforcement approach rather than formally adding the substances to the compounding list. [2]
The policy does not establish that compounded products are FDA-approved, safe or effective. How long the policy will remain in place and what final rulemaking will decide remain open. [1] [2]
Why it matters
This is a meaningful regulatory shift for compounding businesses, but it does not create clinical evidence or product approval. The distinction matters because enforcement discretion and evidence of safety or effectiveness are separate questions.
Editor's note
No treatment advice is included. The HHS notice and AP reporting do not establish safety or efficacy. TODO-review: ‘enforcement discretion’ is rendered as ‘단속 재량’.